首页 > 最新文献

The Australian and New Zealand journal of psychiatry最新文献

英文 中文
Changing trends in quality of media reporting of suicide in the community following a celebrity suicide in India. 印度名人自杀后,媒体对社区自杀报道质量的变化趋势。
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-02 DOI: 10.1177/00048674211009618
Vikas Menon, Sujita Kumar Kar, Ramdas Ransing, Ginni Sharma, Jigyansa Ipsita Pattnaik, Charanya Kaliamoorthy, Natarajan Varadharajan, Srijeeta Mukherjee, Aditya Agrawal, Susanta Kumar Padhy, Sm Yasir Arafat

Objective: Little is known about changes in quality of media reporting of suicide in the community following a celebrity suicide. Our objective was to compare trends in quality of media reporting of suicide, before and after the suicide of an Indian entertainment celebrity, against the World Health Organization suicide reporting guidelines.

Method: Online news portals of English and local language newspapers, as well as television channels, were searched to identify relevant suicide-related news articles. Comparison of reporting characteristics before and after the celebrity suicide was performed using chi-square test or Fisher's exact test.

Results: A total of 3867 eligible news reports were retrieved. There was a significant increase in harmful reporting characteristics, such as reporting the name, age and gender of the deceased (p < 0.001 for all comparisons), mentioning the location (p < 0.001) and reason for suicide (p = 0.04) and including photos of the deceased (p = 0.002) following the celebrity suicide. Helpful reporting practices were less affected; there was a significant rise in inclusion of expert opinion (p = 0.04) and mention of suicide-related warning signs (p = 0.02).

Conclusion: Following a celebrity suicide, significant changes in the quality of media reporting of suicide were noted with an increase in several potentially harmful reporting characteristics.

目的:在名人自杀后,媒体对社区自杀报道质量的变化知之甚少。我们的目的是比较印度一位娱乐名人自杀前后媒体对自杀报道质量的趋势与世界卫生组织自杀报道准则的对比。方法:检索英语和地方语言报纸的在线新闻门户网站以及电视频道,找出与自杀相关的新闻文章。比较名人自杀前后的报道特征采用卡方检验或Fisher精确检验。结果:共检索到3867篇符合条件的新闻报道。在名人自杀后,有害的报道特征显著增加,例如报道死者的姓名、年龄和性别(p p p = 0.04),并包括死者的照片(p = 0.002)。有益的报告做法受到的影响较小;包括专家意见(p = 0.04)和提及自杀相关警告标志(p = 0.02)的人数显著增加。结论:在名人自杀后,媒体对自杀的报道质量发生了显著变化,一些潜在有害的报道特征有所增加。
{"title":"Changing trends in quality of media reporting of suicide in the community following a celebrity suicide in India.","authors":"Vikas Menon,&nbsp;Sujita Kumar Kar,&nbsp;Ramdas Ransing,&nbsp;Ginni Sharma,&nbsp;Jigyansa Ipsita Pattnaik,&nbsp;Charanya Kaliamoorthy,&nbsp;Natarajan Varadharajan,&nbsp;Srijeeta Mukherjee,&nbsp;Aditya Agrawal,&nbsp;Susanta Kumar Padhy,&nbsp;Sm Yasir Arafat","doi":"10.1177/00048674211009618","DOIUrl":"https://doi.org/10.1177/00048674211009618","url":null,"abstract":"<p><strong>Objective: </strong>Little is known about changes in quality of media reporting of suicide in the community following a celebrity suicide. Our objective was to compare trends in quality of media reporting of suicide, before and after the suicide of an Indian entertainment celebrity, against the World Health Organization suicide reporting guidelines.</p><p><strong>Method: </strong>Online news portals of English and local language newspapers, as well as television channels, were searched to identify relevant suicide-related news articles. Comparison of reporting characteristics before and after the celebrity suicide was performed using chi-square test or Fisher's exact test.</p><p><strong>Results: </strong>A total of 3867 eligible news reports were retrieved. There was a significant increase in harmful reporting characteristics, such as reporting the name, age and gender of the deceased (<i>p</i> < 0.001 for all comparisons), mentioning the location (<i>p</i> < 0.001) and reason for suicide (<i>p</i> = 0.04) and including photos of the deceased (<i>p</i> = 0.002) following the celebrity suicide. Helpful reporting practices were less affected; there was a significant rise in inclusion of expert opinion (<i>p</i> = 0.04) and mention of suicide-related warning signs (<i>p</i> = 0.02).</p><p><strong>Conclusion: </strong>Following a celebrity suicide, significant changes in the quality of media reporting of suicide were noted with an increase in several potentially harmful reporting characteristics.</p>","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"81-90"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211009618","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38942202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Treating schizophrenia: Should we emphasise 'first do no harm'? 治疗精神分裂症:我们应该强调“首先不伤害”吗?
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-06-18 DOI: 10.1177/00048674211025696
Tom English, David Castle
{"title":"Treating schizophrenia: Should we emphasise 'first do no harm'?","authors":"Tom English,&nbsp;David Castle","doi":"10.1177/00048674211025696","DOIUrl":"https://doi.org/10.1177/00048674211025696","url":null,"abstract":"","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"8-10"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211025696","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39245389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The 2020 mood disorders clinical practice guidelines: Dazzlingly bedazzling! 2020年心境障碍临床实践指南:眼花缭乱!
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-02 DOI: 10.1177/00048674211010262
Gin S Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Greg Murray, Roger Mulder, Ajeet Singh, Richard Porter
Australian & New Zealand Journal of Psychiatry, 56(1) give misleading results guiding clinical practice. Therefore, we conducted a metaanalysis in a different way by putting NAC-risperidone combination as one group and grouping NAC supplementation to other treatments as another. Our results, which were quite different from those of that meta-analysis (Lee et al., 2021), failed to show effectiveness of NAC supplementation for improving irritability in patients with ASD (Figure 1[a]). Instead, NAC was only effective when used as add-on therapy to risperidone when compared with risperidone treatment alone in respect of improving irritability among patients with ASD (Figure 1[b]). Our findings suggest that current evidence only support the use of NAC as add-on therapy to risperidone for irritability in patients with ASD rather than as supplementation to other treatments.
{"title":"The 2020 mood disorders clinical practice guidelines: Dazzlingly bedazzling!","authors":"Gin S Malhi,&nbsp;Erica Bell,&nbsp;Darryl Bassett,&nbsp;Philip Boyce,&nbsp;Malcolm Hopwood,&nbsp;Greg Murray,&nbsp;Roger Mulder,&nbsp;Ajeet Singh,&nbsp;Richard Porter","doi":"10.1177/00048674211010262","DOIUrl":"https://doi.org/10.1177/00048674211010262","url":null,"abstract":"Australian & New Zealand Journal of Psychiatry, 56(1) give misleading results guiding clinical practice. Therefore, we conducted a metaanalysis in a different way by putting NAC-risperidone combination as one group and grouping NAC supplementation to other treatments as another. Our results, which were quite different from those of that meta-analysis (Lee et al., 2021), failed to show effectiveness of NAC supplementation for improving irritability in patients with ASD (Figure 1[a]). Instead, NAC was only effective when used as add-on therapy to risperidone when compared with risperidone treatment alone in respect of improving irritability among patients with ASD (Figure 1[b]). Our findings suggest that current evidence only support the use of NAC as add-on therapy to risperidone for irritability in patients with ASD rather than as supplementation to other treatments.","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"92-93"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211010262","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38942197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Comorbid substance use in psychosis: Someone else's problem? 精神病共病药物使用:别人的问题?
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-12-09 DOI: 10.1177/00048674211065669
Julia M Lappin
Australian & New Zealand Journal of Psychiatry, 56(1) Substance misuse is common among people who experience psychotic illness, with approximately one-third diagnosed with lifetime comorbid substance misuse (Toftdahl et al., 2016). Detecting and intervening in comorbid substance use is important because it is associated with poorer outcomes across a range of domains including increased rates of not only relapse and re-hospitalisation but also violence, suicide and all-cause mortality (reviewed in Darke et al., 2019). This significant negative prognostic indicator is frequently overlooked both in research, where people with comorbid substance use are often excluded from randomised controlled trials or other experimental studies, and in the clinical setting where substance issues may be considered to fall in the domain of drug and alcohol services. Furthermore, it is possible, even likely, that problematic use of many substances may go undetected in our severe mental illness populations because we do not see substance misuse as our core business, or because we are not exploring all possible drugs that may be in use. So, is it time for us to start to get better at detecting and intervening in substance use? For those clinicians who are motivated to enquire about comorbid substance use as part of a holistic assessment, what are the major substances that we should be inquiring about? Likely, the first drugs that spring to mind in association with psychosis will be cannabis and methamphetamine. It is undoubtedly true that most cases of new-onset psychosis in the context of substance use in Australia, at least in those aged below 30, are related to cannabis, and/or to stimulants, predominantly methamphetamine. The potential for cannabis to increase risk for psychosis has been comprehensively researched and debated over recent decades. Meta-analytic evidence suggests that cannabis use is associated with increased risk for psychosis and in a dose-dependent manner (reviewed in Darke et al., 2019). High-potency cannabis (‘skunk’) contains high concentrations of Δ9tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis. Use is associated with both a higher risk for psychosis and a younger age of its onset. Based on evidence that cannabis use is associated with an earlier onset of psychotic illness, it has also been argued that use may hasten the onset of psychosis in those who are otherwise vulnerable by dint of, for example, familial risk, genetic predisposition and/or environmental factors such as childhood trauma or social deprivation. Methamphetamine is the most common illicitly used amphetamine, with an estimated 37 million users globally (Lappin and Sara, 2019). Use is predominantly of ‘ice’, the high potency crystalline form of methamphetamine. Methamphetamine and its active metabolite amphetamine have long been known to induce psychotic symptoms during use, likely due to their ability to powerfully increase synaptic dopamine. P
{"title":"Comorbid substance use in psychosis: Someone else's problem?","authors":"Julia M Lappin","doi":"10.1177/00048674211065669","DOIUrl":"https://doi.org/10.1177/00048674211065669","url":null,"abstract":"Australian & New Zealand Journal of Psychiatry, 56(1) Substance misuse is common among people who experience psychotic illness, with approximately one-third diagnosed with lifetime comorbid substance misuse (Toftdahl et al., 2016). Detecting and intervening in comorbid substance use is important because it is associated with poorer outcomes across a range of domains including increased rates of not only relapse and re-hospitalisation but also violence, suicide and all-cause mortality (reviewed in Darke et al., 2019). This significant negative prognostic indicator is frequently overlooked both in research, where people with comorbid substance use are often excluded from randomised controlled trials or other experimental studies, and in the clinical setting where substance issues may be considered to fall in the domain of drug and alcohol services. Furthermore, it is possible, even likely, that problematic use of many substances may go undetected in our severe mental illness populations because we do not see substance misuse as our core business, or because we are not exploring all possible drugs that may be in use. So, is it time for us to start to get better at detecting and intervening in substance use? For those clinicians who are motivated to enquire about comorbid substance use as part of a holistic assessment, what are the major substances that we should be inquiring about? Likely, the first drugs that spring to mind in association with psychosis will be cannabis and methamphetamine. It is undoubtedly true that most cases of new-onset psychosis in the context of substance use in Australia, at least in those aged below 30, are related to cannabis, and/or to stimulants, predominantly methamphetamine. The potential for cannabis to increase risk for psychosis has been comprehensively researched and debated over recent decades. Meta-analytic evidence suggests that cannabis use is associated with increased risk for psychosis and in a dose-dependent manner (reviewed in Darke et al., 2019). High-potency cannabis (‘skunk’) contains high concentrations of Δ9tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis. Use is associated with both a higher risk for psychosis and a younger age of its onset. Based on evidence that cannabis use is associated with an earlier onset of psychotic illness, it has also been argued that use may hasten the onset of psychosis in those who are otherwise vulnerable by dint of, for example, familial risk, genetic predisposition and/or environmental factors such as childhood trauma or social deprivation. Methamphetamine is the most common illicitly used amphetamine, with an estimated 37 million users globally (Lappin and Sara, 2019). Use is predominantly of ‘ice’, the high potency crystalline form of methamphetamine. Methamphetamine and its active metabolite amphetamine have long been known to induce psychotic symptoms during use, likely due to their ability to powerfully increase synaptic dopamine. P","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"5-7"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39958645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Neural, behavioural and real-life correlates of social context sensitivity and social reward learning during interpersonal interactions in the schizophrenia spectrum. 精神分裂症患者人际交往中社会情境敏感性和社会奖励学习的神经、行为和现实关联。
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-18 DOI: 10.1177/00048674211010327
Esther Hanssen, Mariët van Buuren, Nienke Van Atteveldt, Imke Lj Lemmers-Jansen, Anne-Kathrin J Fett

Objective: Recent findings suggest that diminished processing of positive contextual information about others during interactions may contribute to social impairment in the schizophrenia spectrum. This could be due to general social context processing deficits or specific biases against positive information. We studied the impact of positive and negative social contextual information during social interactions using functional neuroimaging and probed whether these neural mechanisms were associated with real-life social functioning in schizophrenia spectrum disorders.

Methods: Patients with a schizophrenia spectrum disorder (N = 23) and controls disorder (N = 25) played three multi-round trust games during functional magnetic resonance imaging scanning, with no, positive and negative information about the counterpart's trustworthiness, while all counterparts were programmed to behave trustworthy. The main outcome variable was the height of the shared amount in the trust game, i.e. investment, representing an indication of trust. The first investment in the game was considered to be basic trust, since no behavioural feedback was given yet. We performed region-of-interest analyses and examined the association with real-life social functioning using the experience sampling method.

Results: Social contextual information had no effect on patients' first investments, whereas controls made the lowest investment after negative and the highest investments after positive contextual information was provided. Over trials, patients decreased investments, suggesting reduced social reward learning, whereas controls increased investments in response to behavioural feedback in the negative context. Patients engaged the dorsolateral prefrontal cortex less than controls during context presentation and showed reduced activity within the caudate during repayments. In patients, lower investments were associated with more time spent alone and social exclusion and lower caudate activation was marginally significantly associated with higher perceived social exclusion.

Conclusion: The failure to adapt trust to positive and negative social contexts suggests that patients have a general insensitivity to prior social information, indicating top-down processing impairments. In addition, patients show reduced sensitivity to social reward, i.e. bottom-up processing deficits. Moreover, lower trust and lower neural activation were related to lower real-life social functioning. Together, these findings indicate that improving trust and social interactions in schizophrenia spectrum needs a multi-faceted approach that targets both mechanisms.

目的:最近的研究结果表明,在互动过程中减少对他人的积极背景信息的处理可能会导致精神分裂症谱系中的社会障碍。这可能是由于一般的社会背景处理缺陷或对积极信息的特定偏见。我们利用功能神经成像技术研究了积极和消极的社会背景信息在社会互动中的影响,并探讨了这些神经机制是否与精神分裂症谱系障碍患者现实生活中的社会功能有关。方法:23例精神分裂症谱系障碍患者(N = 23)和25例对照组患者(N = 25)在功能性磁共振成像扫描过程中进行3次多回合信任游戏,分别给予对方无、正、负可信信息,同时对所有的对方进行编程,使其表现出可信行为。主要的结果变量是信任博弈中共享金额的高度,即投资,代表信任的指示。在游戏中的第一次投资被认为是基本信任,因为还没有行为反馈。我们进行了兴趣区域分析,并使用经验抽样方法检查了与现实生活中的社会功能的联系。结果:社会背景信息对患者的首次投资没有影响,而对照组在提供负面背景信息后投资最低,在提供积极背景信息后投资最高。在试验中,患者减少了投资,这表明社会奖励学习减少了,而对照组增加了对消极环境下行为反馈的投资。在情境呈现过程中,患者的背外侧前额叶皮层活动比对照组少,在偿还过程中尾状核的活动减少。在患者中,较低的投入与更多的独处时间和社会排斥有关,较低的尾状核激活与较高的感知社会排斥有轻微的显著相关。结论:信任不能适应积极和消极的社会环境,表明患者对先前的社会信息普遍不敏感,表明自上而下的加工障碍。此外,患者对社会奖励的敏感性降低,即自下而上的加工缺陷。此外,较低的信任和较低的神经激活与较低的现实社会功能有关。总之,这些发现表明,改善精神分裂症患者的信任和社会互动需要一种针对这两种机制的多方面方法。
{"title":"Neural, behavioural and real-life correlates of social context sensitivity and social reward learning during interpersonal interactions in the schizophrenia spectrum.","authors":"Esther Hanssen,&nbsp;Mariët van Buuren,&nbsp;Nienke Van Atteveldt,&nbsp;Imke Lj Lemmers-Jansen,&nbsp;Anne-Kathrin J Fett","doi":"10.1177/00048674211010327","DOIUrl":"https://doi.org/10.1177/00048674211010327","url":null,"abstract":"<p><strong>Objective: </strong>Recent findings suggest that diminished processing of positive contextual information about others during interactions may contribute to social impairment in the schizophrenia spectrum. This could be due to general social context processing deficits or specific biases against positive information. We studied the impact of positive and negative social contextual information during social interactions using functional neuroimaging and probed whether these neural mechanisms were associated with real-life social functioning in schizophrenia spectrum disorders.</p><p><strong>Methods: </strong>Patients with a schizophrenia spectrum disorder (<i>N</i> = 23) and controls disorder (<i>N</i> = 25) played three multi-round trust games during functional magnetic resonance imaging scanning, with no, positive and negative information about the counterpart's trustworthiness, while all counterparts were programmed to behave trustworthy. The main outcome variable was the height of the shared amount in the trust game, i.e. investment, representing an indication of trust. The first investment in the game was considered to be basic trust, since no behavioural feedback was given yet. We performed region-of-interest analyses and examined the association with real-life social functioning using the experience sampling method.</p><p><strong>Results: </strong>Social contextual information had no effect on patients' first investments, whereas controls made the lowest investment after negative and the highest investments after positive contextual information was provided. Over trials, patients decreased investments, suggesting reduced social reward learning, whereas controls increased investments in response to behavioural feedback in the negative context. Patients engaged the dorsolateral prefrontal cortex less than controls during context presentation and showed reduced activity within the caudate during repayments. In patients, lower investments were associated with more time spent alone and social exclusion and lower caudate activation was marginally significantly associated with higher perceived social exclusion.</p><p><strong>Conclusion: </strong>The failure to adapt trust to positive and negative social contexts suggests that patients have a general insensitivity to prior social information, indicating top-down processing impairments. In addition, patients show reduced sensitivity to social reward, i.e. bottom-up processing deficits. Moreover, lower trust and lower neural activation were related to lower real-life social functioning. Together, these findings indicate that improving trust and social interactions in schizophrenia spectrum needs a multi-faceted approach that targets both mechanisms.</p>","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"59-70"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211010327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38913238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Odour identification impairment is a trait but not a disease-specific marker for bipolar disorders: Comparisons of bipolar disorder with different episodes, major depressive disorder and schizophrenia. 气味识别障碍是双相情感障碍的一种特征,但不是疾病特异性标志物:双相情感障碍与不同发作、重度抑郁症和精神分裂症的比较
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-03-16 DOI: 10.1177/0004867421998774
Shu-Bin Li, Ze-Tian Li, Zhi-Hong Lyu, Xiao-Yuan Zhang, Lai-Quan Zou

Objective: Olfactory deficits have been reported in bipolar disorder, but this finding is controversial. This study investigated whether olfactory deficit can serve as a specific marker for bipolar disorder by comparing olfactory function in different mood episodes of bipolar disorder. We also compared olfactory function in bipolar disorder and other mental disorders - namely, major depressive disorder and schizophrenia.

Methods: The study consisted of two experiments. Experiment 1 enrolled 175 bipolar disorder patients (70 depressed subgroup, 70 manic subgroup and 35 euthymic subgroup) and 47 controls. Experiment 2 enrolled the participants from Experiment 1, along with 85 major depressive disorder and 90 schizophrenia patients. The Sniffin' Sticks test was used to evaluate odour identification ability and odour threshold (as a measure of odour sensitivity). The Hamilton Depression Rating Scale and Young Mania Rating Scale were used to assess depressive symptoms in all subjects and manic symptoms in bipolar disorder patients, respectively. We also used the Positive and Negative Syndrome Scale to assess clinical symptoms in schizophrenia patients.

Results: All three bipolar disorder patient subgroups (depressed, manic and euthymic subgroup) showed reduced odour identification ability compared to controls; however, only patients in the acute phase of a mood episode (depressed, and manic subgroup) showed impaired odour sensitivity. Clinical symptoms were negatively correlated with odour sensitivity but not odour identification ability. Bipolar disorder and major depressive disorder patients showed less odour identification and sensitivity impairment than schizophrenia patients.

Conclusion: Odour sensitivity is a potential dopaminergic marker for distinguishing between bipolar disorder patients in acute phase vs remission, while odour identification is a trait but a nonspecific marker of bipolar disorder.

目的:双相情感障碍有嗅觉缺陷的报道,但这一发现存在争议。本研究通过比较双相情感障碍不同情绪发作的嗅觉功能,探讨嗅觉缺陷是否可以作为双相情感障碍的特异性标志物。我们还比较了双相情感障碍和其他精神障碍的嗅觉功能,即重度抑郁症和精神分裂症。方法:研究分为两个实验。实验1共纳入175例双相情感障碍患者(抑郁亚组70例,躁狂亚组70例,心境亚组35例)和47例对照。实验2招募了实验1的参与者,以及85名重度抑郁症患者和90名精神分裂症患者。嗅探棒测试用于评估气味识别能力和气味阈值(作为气味敏感性的衡量标准)。汉密尔顿抑郁评定量表和青年躁狂症评定量表分别用于评估所有受试者的抑郁症状和双相情感障碍患者的躁狂症状。我们还使用阳性和阴性综合征量表来评估精神分裂症患者的临床症状。结果:与对照组相比,所有三个双相情感障碍患者亚组(抑郁、躁狂和平静亚组)的气味识别能力都有所降低;然而,只有在情绪发作的急性期(抑郁和躁狂亚组)的患者表现出气味敏感性受损。临床症状与气味敏感性呈负相关,但与气味识别能力无关。双相情感障碍和重度抑郁症患者的气味识别和敏感性损伤程度低于精神分裂症患者。结论:气味敏感性是区分双相情感障碍患者急性期和缓解期的潜在多巴胺能标志物,而气味识别是双相情感障碍的一种特征,但非特异性标志物。
{"title":"Odour identification impairment is a trait but not a disease-specific marker for bipolar disorders: Comparisons of bipolar disorder with different episodes, major depressive disorder and schizophrenia.","authors":"Shu-Bin Li,&nbsp;Ze-Tian Li,&nbsp;Zhi-Hong Lyu,&nbsp;Xiao-Yuan Zhang,&nbsp;Lai-Quan Zou","doi":"10.1177/0004867421998774","DOIUrl":"https://doi.org/10.1177/0004867421998774","url":null,"abstract":"<p><strong>Objective: </strong>Olfactory deficits have been reported in bipolar disorder, but this finding is controversial. This study investigated whether olfactory deficit can serve as a specific marker for bipolar disorder by comparing olfactory function in different mood episodes of bipolar disorder. We also compared olfactory function in bipolar disorder and other mental disorders - namely, major depressive disorder and schizophrenia.</p><p><strong>Methods: </strong>The study consisted of two experiments. Experiment 1 enrolled 175 bipolar disorder patients (70 depressed subgroup, 70 manic subgroup and 35 euthymic subgroup) and 47 controls. Experiment 2 enrolled the participants from Experiment 1, along with 85 major depressive disorder and 90 schizophrenia patients. The Sniffin' Sticks test was used to evaluate odour identification ability and odour threshold (as a measure of odour sensitivity). The Hamilton Depression Rating Scale and Young Mania Rating Scale were used to assess depressive symptoms in all subjects and manic symptoms in bipolar disorder patients, respectively. We also used the Positive and Negative Syndrome Scale to assess clinical symptoms in schizophrenia patients.</p><p><strong>Results: </strong>All three bipolar disorder patient subgroups (depressed, manic and euthymic subgroup) showed reduced odour identification ability compared to controls; however, only patients in the acute phase of a mood episode (depressed, and manic subgroup) showed impaired odour sensitivity. Clinical symptoms were negatively correlated with odour sensitivity but not odour identification ability. Bipolar disorder and major depressive disorder patients showed less odour identification and sensitivity impairment than schizophrenia patients.</p><p><strong>Conclusion: </strong>Odour sensitivity is a potential dopaminergic marker for distinguishing between bipolar disorder patients in acute phase vs remission, while odour identification is a trait but a nonspecific marker of bipolar disorder.</p>","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"71-80"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/0004867421998774","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25485428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Positioning TMS. 定位“颅磁刺激”。
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-13 DOI: 10.1177/00048674211011259
Mark George, Saxby Pridmore
Malhi et al. (2021) have given reasons for transcranial magnetic stimulation (TMS) not being prominently positioned on the 2020 Royal Australian and New Zealand College of Psychiatrists (RANZCP) mood disorders guidelines algorithm. They state positioning is based on clinical effect, ‘(b)ut rTMS has been posited as a treatment for depression largely because of its mechanism of action and not because of its clinical effect’. It is not stated who or when this positing was performed. We have been involved with TMS since the early 1990s and offer historical facts. For much of the 20th century, it was known that (1) ECT is effective in the treatment of MDD and (2) because the skull is a poor conductor, current electricity cannot be focused and spreads out across the brain causing the side-effects of memory loss and seizure. Psychiatrists around the world explored the application of focused electrical energy (electromagnetic technology) to the brain of people with MDD (with fingers crossed that depolarization would not spread). There was no extravagant expectation of replacing ECT – rather, it was hoped to harness some ECT magic with fewer side-effects. The first study of TMS in MDD was conducted in Germany in 1993 – stimulation was applied over the vertex. In 1995, based on the pathophysiology of MDD, Mark George and colleagues conducted a trial with TMS applied to the left dorsolateral prefrontal cortex – this has remained a potent option for the last quarter century. From the beginning, TMS has been offered to people who have not responded to psychotherapy and medication – treatments which are widely available, proven and relatively inexpensive. TMS involves set-up costs and professional clinical supervision. In the early years, in addition to expense, TMS was reserved for nonresponders to other treatments because of the possibility (unrealized) of side-effects. With each failed treatment, the chance of a subsequent treatment achieving a good outcome is greatly reduced. This is sometimes overlooked when the general outcome of TMS is being evaluated – because most of those who come to TMS have failed at least two other treatments, the achievement of >40% response (Fitzgerald et al., 2016) is remarkable and valuable. While ECT may be more efficacious, TMS has a better balance of efficacy and acceptability. If TMS is to be positioned on an algorithm, for the last two decades, the general recommendation and specific requirement of insurers has been – after two failed treatment attempts and before ECT. This position could be reasonably retained.
{"title":"Positioning TMS.","authors":"Mark George,&nbsp;Saxby Pridmore","doi":"10.1177/00048674211011259","DOIUrl":"https://doi.org/10.1177/00048674211011259","url":null,"abstract":"Malhi et al. (2021) have given reasons for transcranial magnetic stimulation (TMS) not being prominently positioned on the 2020 Royal Australian and New Zealand College of Psychiatrists (RANZCP) mood disorders guidelines algorithm. They state positioning is based on clinical effect, ‘(b)ut rTMS has been posited as a treatment for depression largely because of its mechanism of action and not because of its clinical effect’. It is not stated who or when this positing was performed. We have been involved with TMS since the early 1990s and offer historical facts. For much of the 20th century, it was known that (1) ECT is effective in the treatment of MDD and (2) because the skull is a poor conductor, current electricity cannot be focused and spreads out across the brain causing the side-effects of memory loss and seizure. Psychiatrists around the world explored the application of focused electrical energy (electromagnetic technology) to the brain of people with MDD (with fingers crossed that depolarization would not spread). There was no extravagant expectation of replacing ECT – rather, it was hoped to harness some ECT magic with fewer side-effects. The first study of TMS in MDD was conducted in Germany in 1993 – stimulation was applied over the vertex. In 1995, based on the pathophysiology of MDD, Mark George and colleagues conducted a trial with TMS applied to the left dorsolateral prefrontal cortex – this has remained a potent option for the last quarter century. From the beginning, TMS has been offered to people who have not responded to psychotherapy and medication – treatments which are widely available, proven and relatively inexpensive. TMS involves set-up costs and professional clinical supervision. In the early years, in addition to expense, TMS was reserved for nonresponders to other treatments because of the possibility (unrealized) of side-effects. With each failed treatment, the chance of a subsequent treatment achieving a good outcome is greatly reduced. This is sometimes overlooked when the general outcome of TMS is being evaluated – because most of those who come to TMS have failed at least two other treatments, the achievement of >40% response (Fitzgerald et al., 2016) is remarkable and valuable. While ECT may be more efficacious, TMS has a better balance of efficacy and acceptability. If TMS is to be positioned on an algorithm, for the last two decades, the general recommendation and specific requirement of insurers has been – after two failed treatment attempts and before ECT. This position could be reasonably retained.","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"98-99"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211011259","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38988044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why does clozapine cause increased rebound psychosis and catatonia, compared to quetiapine? 与喹硫平相比,为什么氯氮平会导致反弹性精神病和紧张症增加?
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-10 DOI: 10.1177/00048674211011246
Tarun Bastiampillai, Wini Wei Lam Woo, Sherry Kit Wa Chan, Pramod C Nair
1 Department of Psychiatry, Monash University, Clayton, VIC, Australia 2 Discipline of Psychiatry, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia 3 Mental Health Division, Southern Adelaide Local Health Network, Adelaide, SA, Australia 4 Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR 5 Discipline of Clinical Pharmacology, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia
{"title":"Why does clozapine cause increased rebound psychosis and catatonia, compared to quetiapine?","authors":"Tarun Bastiampillai,&nbsp;Wini Wei Lam Woo,&nbsp;Sherry Kit Wa Chan,&nbsp;Pramod C Nair","doi":"10.1177/00048674211011246","DOIUrl":"https://doi.org/10.1177/00048674211011246","url":null,"abstract":"1 Department of Psychiatry, Monash University, Clayton, VIC, Australia 2 Discipline of Psychiatry, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia 3 Mental Health Division, Southern Adelaide Local Health Network, Adelaide, SA, Australia 4 Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR 5 Discipline of Clinical Pharmacology, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"98"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211011246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38887226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The case for discontinuation of the 'discontinuation syndrome'. 中止“中止综合症”的案例。
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-08-30 DOI: 10.1177/00048674211043443
William Lugg
Australian & New Zealand Journal of Psychiatry, 56(1) robust testing. For example, our Windows of Antidepressant Response Paradigm (WARP) may be useful in devising future clinical trials, especially where agents purported to have rapid actions are investigated. This would also test the utility of the paradigm and allow it to be further refined, if found to be useful. Similarly, our Channelling Response Paradigm (CRP) can perhaps provide a framework for naturalistic treatment studies conducted in real-world populations, in a similar vein to landmark studies such as STAR*D (Rush et al., 2004). Dr Rosenman’s description of the guidelines as ‘intellectually dazzling’ is balanced by his well-founded concern that psychiatric diagnoses of disorders and paradigms for psychiatric management need to constantly evolve and strive harder to better capture reality. While we share his, and arguably mainstream psychiatry’s, belief that the current binary diagnoses do not adequately capture the descriptive landscape of mental health (which has prominent dimensional components like A, C and E), we have had to be pragmatic and construct a guideline on the available evidence which derives principally from a taxonomy based on binary diagnoses. We thus extend an invitation to everyone to assist us in further bedazzling future iterations of the guidelines and help us escape the confines of our thinking.
{"title":"The case for discontinuation of the 'discontinuation syndrome'.","authors":"William Lugg","doi":"10.1177/00048674211043443","DOIUrl":"https://doi.org/10.1177/00048674211043443","url":null,"abstract":"Australian & New Zealand Journal of Psychiatry, 56(1) robust testing. For example, our Windows of Antidepressant Response Paradigm (WARP) may be useful in devising future clinical trials, especially where agents purported to have rapid actions are investigated. This would also test the utility of the paradigm and allow it to be further refined, if found to be useful. Similarly, our Channelling Response Paradigm (CRP) can perhaps provide a framework for naturalistic treatment studies conducted in real-world populations, in a similar vein to landmark studies such as STAR*D (Rush et al., 2004). Dr Rosenman’s description of the guidelines as ‘intellectually dazzling’ is balanced by his well-founded concern that psychiatric diagnoses of disorders and paradigms for psychiatric management need to constantly evolve and strive harder to better capture reality. While we share his, and arguably mainstream psychiatry’s, belief that the current binary diagnoses do not adequately capture the descriptive landscape of mental health (which has prominent dimensional components like A, C and E), we have had to be pragmatic and construct a guideline on the available evidence which derives principally from a taxonomy based on binary diagnoses. We thus extend an invitation to everyone to assist us in further bedazzling future iterations of the guidelines and help us escape the confines of our thinking.","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"93-95"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39370920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic treatment in clinical high risk for psychosis: Iatrogenesis related to dopamine supersensitivity psychosis? 临床精神病高危患者的抗精神病药物治疗:与多巴胺超敏感性精神病相关的医源性?
IF 4.6 Pub Date : 2022-01-01 Epub Date: 2021-05-10 DOI: 10.1177/00048674211011243
Tarun Bastiampillai, Sherry Kit Wa Chan, Stephen Allison, David Copolov, Jeffrey Cl Looi
1 Department of Psychiatry, Monash University, Clayton, VIC, Australia 2 College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia 3 Consortium of Australian-Academic Psychiatrists for Independent Policy and Research Analysis (CAPIPRA), Canberra, ACT, Australia 4 Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR 5 The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pok Fu Lam, Hong Kong 6 Academic Unit of Psychiatry and Addiction Medicine, The Australian National University Medical School, Canberra Hospital, Canberra, ACT, Australia
{"title":"Antipsychotic treatment in clinical high risk for psychosis: Iatrogenesis related to dopamine supersensitivity psychosis?","authors":"Tarun Bastiampillai,&nbsp;Sherry Kit Wa Chan,&nbsp;Stephen Allison,&nbsp;David Copolov,&nbsp;Jeffrey Cl Looi","doi":"10.1177/00048674211011243","DOIUrl":"https://doi.org/10.1177/00048674211011243","url":null,"abstract":"1 Department of Psychiatry, Monash University, Clayton, VIC, Australia 2 College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia 3 Consortium of Australian-Academic Psychiatrists for Independent Policy and Research Analysis (CAPIPRA), Canberra, ACT, Australia 4 Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong SAR 5 The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pok Fu Lam, Hong Kong 6 Academic Unit of Psychiatry and Addiction Medicine, The Australian National University Medical School, Canberra Hospital, Canberra, ACT, Australia","PeriodicalId":117457,"journal":{"name":"The Australian and New Zealand journal of psychiatry","volume":" ","pages":"97"},"PeriodicalIF":4.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/00048674211011243","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38967228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
The Australian and New Zealand journal of psychiatry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1